Karolinska Development AB has entered into an agreement with Mayo Clinic to evaluate and identify commercialization opportunities in Mayo’s life science innovations to improve patient care. Both companies will be able to further invest in commercially interesting innovations, jointly or independently.
Torbjörn Bjerke, chief executive officer of Karolinska Development, said, "Karolinska Development invests in world-class innovations, currently from the best Nordic institutions. Mayo Clinic is one of the finest medical institutions; it is a globally recognized powerhouse of patient treatment and life sciences innovation, similar to the Karolinska Institutet. Through this agreement, Karolinska Development will not only gain access to an additional continuous flow of new ideas and projects, but we will also be able to showcase our own innovations for an excellent investor in life science.”
James Rogers, chair of the Mayo Clinic Venture, said, "We are pleased to announce our collaboration with Karolinska Development to identify, develop, and commercialize the new ideas being generated by Mayo physicians and scientists. Karolinska Development has a demonstrated ability to develop early stage ideas into clinically tested products for the benefit of patient care. We are looking forward to working together on advancing innovative technologies to a commercial and clinical endpoint."